Isabelle Boutron

From Wikipedia, the free encyclopedia
Isabelle Boutron
Born14 February 1971
NationalityFrench
Alma materPierre and Marie Curie University
OccupationProfessor, researcher

Isabelle Boutron (born February 14, 1971) is a professor of epidemiology at the Paris Descartes University[1] and head of the INSERM- METHODS team within the Centre of Research in Epidemiology and Statistics (CRESS). She was originally trained in rheumatology and later switched to a career in epidemiology and public health. She is also deputy director of the French EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Centre, director of Cochrane France and co-convenor of the Bias Methods group of the Cochrane Collaboration.

Biography and education[]

Boutron graduated from the Pierre and Marie Curie University in rheumatology in 2002 and obtained her PhD in epidemiology in 2006. She was a postdoctoral fellow in the Centre for Statistics in Medicine, University of Oxford from 2008 to 2009, working under Douglas Altman.

After being trained in rheumatology, Boutron was awarded of a fellowship from the French Ministry of Health and a 2-year fellowship from the Assistance Publique - Hôpitaux de Paris. With these fellowships, she switched her career focus to epidemiology and public health. She was awarded a PhD in epidemiology in 2006 and became assistant Professor of Epidemiology in the Paris Diderot University in the Department of Epidemiology and Biostatistics directed by Dr. Philippe Ravaud. After a postdoctoral position in the University of Oxford, she joined the Paris Descartes University as associate professor (2009-2012) and professor since 2012.

Scientific activities[]

Boutron's research activities mainly focus on investigating how clinical research is planned, conducted, and reported. She has worked on the internal and external validity of non-pharmacological trials, and co-led the extension of the CONSORT statement on reporting treatment trials for nonpharmacologic treatments.[2][3] Along with her colleagues she edited a book entitled “Randomized Clinical Trials of Nonpharmacological Treatments.” She also investigates the distorted dissemination of research finding through publication bias, selective reporting of outcomes and spin defined as a distorted interpretation of research findings. Boutron has demonstrated the high prevalence of such distortion in the published scientific literature[4][5] and shown how the biased presentation, and interpretation of research results may bias the interpretation of readers,[6] which is a critically important aspect of the knowledge translation process.

Boutron has published more than 100 peer-reviewed articles, with 5 highly cited (i.e.top 1%) articles as first or second author. She is an academic editor for the academic journals [[BMC Med] and [PLoS Biology]]. She is responsible for the teaching programs in Clinical Epidemiology and Public Health, for medical students at Université de Paris, and is co-leader (with Pr. Ravaud) of the international Master 2 program, Comparative Effectiveness Research

Academic awards and honors[]

  • Award Louis-Daniel Beauperthuy, Académie des sciences (2014)

Personal[]

Isabelle Boutron is married to Emmanuel Boutron. She has two children: Antoine born in 1999 and Augustin born in 2003.[citation needed]

References[]

  1. ^ "Boutron, Isabelle (Prof.)". Université Paris Descartes. 2015. Retrieved 7 June 2015.
  2. ^ Boutron, I; Moher, D; Altman, DG; Schulz, KF; Ravaud, P (2008). "Extending the CONSORT statement to randomized trials of nonpharmacologic treatment; explanation and elaboration". Ann Intern Med. 148 (4): 295–309. doi:10.7326/0003-4819-148-4-200802190-00008. PMID 18283207.
  3. ^ Boutron, I; Moher, D; Altman, DG; Schulz, KF; Ravaud, P (2008). "Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments". Ann Intern Med. 148 (4): W60–W66. doi:10.7326/0003-4819-148-4-200802190-00008-w1. PMID 18283201.
  4. ^ Boutron, I; Dutton, S; Ravaud, P; Altman, DG (2010). "Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes". JAMA. 303 (20): 2058–2064. doi:10.1001/jama.2010.651. PMID 20501928.
  5. ^ Yavchitz, A; Boutron, I; Bafeta, A; Marroun, I; Charles, P; Mantz, J; Ravaud, P (2012). "Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study". PLoS Med. 9 (9): e1001308. doi:10.1371/journal.pmed.1001308. PMC 3439420. PMID 22984354.
  6. ^ Boutron, I; Altman, DG; Hopewell, S; Vera-Badillo, F; Tannock, I; Ravaud, P (2014). "Impact of spin in the abstract of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial". J Clin Oncol. 32 (36): 4120–4126. doi:10.1200/JCO.2014.56.7503. PMID 25403215.
Retrieved from ""